Browsing: lung cancer

Press Release – Roche’s Tecentriq® SC (atezolizumab) becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Singapore, reducing treatment time to a few minutes

By 1
Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

Log In or Register as a healthcare professional to read the full article.

Congress Allocates P1.25 Billion for Cancer Assistance Fund (CAF)

By 1

The eight priority cancer types identified by the DoH include the following. They are breast cancer, childhood cancers, gynecologic cancers, liver cancer (including colorectal and other digestive tract cancers), head and neck cancers (including thyroid), lung cancer, and prostate, renal, and urinary bladder cancer. The CAF aims to address the most pressing needs within cancer care and treatment by focusing on these priority areas.

Each cancer type presents unique challenges in prevention, early detection, and treatment. The allocation of funds for these specific areas reflects a strategic approach to resource allocation. This ensures that interventions are targeted and effective in addressing the burden of cancer across different population groups.